ASCIMINIB

asciminib 40 mg tablet, 60

ASCIMINIB (13260X)

asciminib 40 mg tablet, 60
13260X
Body System:
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Initial PBS-subsidised treatment for patients with T315I mutation

Restriction

Indication: Chronic Myeloid Leukaemia (CML)
Treatment phase: Continuing Treatment for patients with T315I mutation
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 5 Max qty units: 300 # of repeats: 5 DPMQ: $30,225.43 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Scemblix